CC
AXSM icon

Centiva Capital’s Axsome Therapeutics AXSM Stock Holding History

Centiva Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,288
Closed -$218K – 1828
2026
Q1 		$218K Buy
+1,288
New +$222K ﹤0.01% 1231
2025
Q2 		– Sell
-2,820
Closed -$329K – 1531
2025
Q1 		$329K Buy
+2,820
New +$321K 0.01% 1033
2020
Q3 		– Sell
-5,149
Closed -$424K – 694
2020
Q2 		$424K Buy
+5,149
New +$396K 0.03% 331

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Centiva Capital's AXSM Position: Q2 2026 in Review

Centiva Capital sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 1,288 shares — an estimated $218K sold.

Centiva Capital first reported a position in AXSM in Q2 2020 and held it in 3 quarters. The position peaked at $424K in Q2 2020. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Centiva Capital reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 1,288 Axsome Therapeutics shares in Q2 2026, an estimated $218K.
  • Centiva Capital first reported a position in Axsome Therapeutics in Q2 2020 and held it in 3 quarters.
  • Centiva Capital's Axsome Therapeutics position peaked at $424K in Q2 2020.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.